Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha

FEBS Lett. 1999 Aug 27;457(2):219-22. doi: 10.1016/s0014-5793(99)01035-2.

Abstract

We compared the anti-HIV-1 activity of CC-chemokine LD78beta with that of MIP-1alpha, another CC-chemokine which shows 94% sequence homology with LD78beta. Despite its close similarity to MIP-1alpha, the anti-HIV-1 activity of LD78beta appeared to be nearly 10 times higher than that of MIP-1alpha. Mutagenesis of MIP-1alpha showed that the N-terminal additional tetrapeptide, which was present in LD78beta and absent in MIP-1alpha, is responsible for enhanced anti-HIV-1 activity. The N-terminal structure-function relationship of LD78beta described here will be of value in understanding the chemokine-receptor interactions and designing anti-HIV-1 compounds based on LD78beta.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-HIV Agents / metabolism
  • Anti-HIV Agents / pharmacology*
  • CD4 Antigens / metabolism
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokines / metabolism
  • Chemokines / pharmacology
  • Dipeptidyl Peptidase 4 / metabolism
  • Genetic Vectors
  • HIV-1 / drug effects*
  • Haplorhini
  • Humans
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / metabolism
  • Macrophage Inflammatory Proteins / metabolism
  • Macrophage Inflammatory Proteins / pharmacology*
  • Peptides / metabolism
  • Peptides / pharmacology
  • Respirovirus / genetics

Substances

  • Anti-HIV Agents
  • CD4 Antigens
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokines
  • Macrophage Inflammatory Proteins
  • Peptides
  • Dipeptidyl Peptidase 4